Policy UpdatesMedicaidJune 9, 2023

Clinical Criteria updates for December 2022

Clinical Criteria updates

On May 20, 2022, August 19, 2022, September 12, 2022, November 18, 2022, December 12, 2022, and January 12, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

Please share this notice with other providers in your practice and office staff.

Please note: 

  • The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective date

Document number

Clinical Criteria title

New or revised

September 10, 2023

*CC-0226

Elahere (mirvetuximab)

New

September 10, 2023

*CC-0227

Briumvi (ublituximab)

New

September 10, 2023

*CC-0228

Leqembi (lecanemab)

New

September 10, 2023

*CC-0229

Sunlenca (lenacapavir)

New

September 10, 2023

CC-0029

Dupixent (dupilumab) 

Revised

September 10, 2023

CC-0185

Oxlumo (lumasiran)

Revised

September 10, 2023

*CC-0072

Selective Vascular Endothelial Growth Factor (VEGF) Inhibitors

Revised

September 10, 2023

CC-0130

Imfinzi (durvalumab)

Revised

September 10, 2023

CC-0223

Imjudo (tremelimumab-actl)

Revised

September 10, 2023

CC-0145

Libtayo (cemiplimab-rwlc)

Revised

September 10, 2023

CC-0092

Adcetris (brentuximab vedotin)

Revised

September 10, 2023

CC-0128

Tecentriq (atezolizumab)

Revised

September 10, 2023

*CC-0107

Bevacizumab for Non-ophthalmologic Indications

Revised

September 10, 2023

*CC-0166

Trastuzumab Agents

Revised

September 10, 2023

*CC-0182

Iron Agents

Revised

September 10, 2023

*CC-0002

Colony Stimulating Factor Agents

Revised

September 10, 2023

*CC-0075

Rituximab agents for Non-Oncologic Indications

Revised

September 10, 2023

*CC-0001

Erythropoiesis Stimulating Agents

Revised

September 10, 2023

*CC-0062

Tumor Necrosis Factor Antagonists

Revised

September 10, 2023

*CC-0167

Rituximab Agents for Oncologic Indications

Revised

CABC-CD-020008-23-CPN19724

PUBLICATIONS: July 2023 Provider Newsletter